Dual targeting of CD155 augments the antitumor efficacy of ROR1-CAR-T cells in ovarian cancer
CD155 emerges as a promising therapeutic target for CAR-T therapy in OC. The bispecific CAR-T construct that co-targets CD155 and ROR1 demonstrates superior and durable tumoricidal activity, offering new perspectives on OC targeted therapy.
Authors
- Yingjun Ye
- Chao Cheng
- Xiaowen He
- Shaohua Xu
- Jiacheng Shen
- Huajing Wang
- Tingwei Liu
Institutions
- Université Oran 1 Ahmed Ben Bella (DZ)
- Shanghai First Maternity and Infant Hospital (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2026-01-27
- DOI
- https://doi.org/10.1007/s00262-025-04283-x
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Shanghai
- National Natural Science Foundation of China